{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:11:18Z","timestamp":1790701878363,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109347","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:50:04Z","timestamp":1772038204000},"page":"109347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5398-2357","authenticated-orcid":false,"given":"Siddhartha","family":"Goutam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun A.","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3998-9489","authenticated-orcid":false,"given":"Hans","family":"Alday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Dawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-5398","authenticated-orcid":false,"given":"Carrie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam J.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lungcan.2026.109347_b0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109347_b0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non\u2013small-cell lung cancer","volume":"24","author":"Aung","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109347_b0015","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109347_b0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109347_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109347_b0030","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/art.42961","article-title":"The risk of lung cancer in rheumatoid arthritis and rheumatoid arthritis\u2013associated interstitial lung disease","volume":"76","author":"Brooks","year":"2024","journal-title":"Arthrit. Rheumatol."},{"issue":"May","key":"10.1016\/j.lungcan.2026.109347_b0035","first-page":"1","article-title":"Association between systemic lupus erythematosus and cancer morbidity and mortality: findings from cohort studies","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109347_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sj\u00f6gren\u2019s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109347_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000492","article-title":"Effectiveness and safety of immune checkpoint inhibitors in cancer patients with autoimmune disease: a retrospective cohort study","volume":"47","author":"Raghavan","year":"2024","journal-title":"J. Immunother."},{"key":"10.1016\/j.lungcan.2026.109347_b0050","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Cancer Therapy Evaluation Program (CTEP) [Internet]. 2017;155. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.lungcan.2026.109347_b0055","series-title":"Stata Statistical Software: Release 18","author":"Statacorp","year":"2024"},{"key":"10.1016\/j.lungcan.2026.109347_b0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2021.04.004","article-title":"Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials","volume":"151","author":"Gan","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109347_b0065","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","article-title":"Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers","volume":"7","author":"Parikh","year":"2021","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2026.109347_b0070","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non\u2013small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109347_b0075","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2458948","article-title":"Immune checkpoint inhibitors in cancer patients with autoimmune disease: safety and efficacy","volume":"21","author":"Le","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109347_b0080","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","article-title":"Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology","volume":"70","author":"Hoa","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109347_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheumatol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109347_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2020-000538","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study","volume":"8","author":"Martinez Chanza","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109347_b0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109347_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109347_b0105","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109347_b0110","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor\u2013induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin. Rheumatol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:47:28Z","timestamp":1790700448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"alternative-id":["S0169500226000917"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109347","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109347"}}